CAR-Engineered Immune Progenitors Open New Front in Cancer Immunotherapy
Scientists expand granulocyte-monocyte progenitors into a scalable CAR platform that infiltrates tumors and fights leukemia and solid cancers.
Summary
Researchers at USC and Stanford have solved a major bottleneck in macrophage-based cancer immunotherapy: the inability to grow enough engineered immune cells outside the body. By developing special culture conditions, they enabled large-scale expansion of granulocyte-monocyte progenitors — early immune cell precursors — from both mice and humans. These expanded cells were then engineered with chimeric antigen receptors, or CARs, targeting leukemia and HER2-positive breast tumors. After infusion, the cells homed to blood-forming niches, produced tumor-infiltrating macrophages, and suppressed cancer growth. A novel CAR design also recruited the host's own immune cells and enabled activity even across genetic mismatches, opening doors to off-the-shelf allogeneic therapies. The study was published in Cell in June 2026.
Detailed Summary
Macrophage-based cancer immunotherapy has long held theoretical promise but struggled with practical limitations: these immune cells expand poorly outside the body, are difficult to genetically engineer, and distribute poorly after infusion. A new study published in Cell addresses these barriers head-on by establishing granulocyte-monocyte progenitors (GMPs) as a renewable, engineerable platform for cellular immunotherapy.
Researchers developed defined culture conditions that sustain long-term expansion of mouse and human GMPs while preserving their identity and ability to mature into functional myeloid cells. A key mechanistic discovery was the identification of myeloperoxidase — an enzyme previously known for its antimicrobial role — as a regulator of GMP proliferation, revealing an unexpected target for controlling progenitor growth.
Engineered GMPs demonstrated robust in vivo performance after adoptive transfer. They engrafted into hematopoietic niches, produced sustained donor-derived myelopoiesis, and restored antibacterial immunity in mouse models of chronic granulomatous disease — a primary immunodeficiency. More strikingly, GMPs armed with chimeric antigen receptors (CARs) suppressed both CD19-positive leukemia and HER2-positive solid tumors across multiple preclinical models.
The team introduced a novel CAR architecture incorporating an IgG Fc domain, which recruits host phagocytes via Fc receptors and enables cross-MHC T cell priming. This design enhanced efficacy in immunocompetent allogeneic cancer models, a critical step toward off-the-shelf cellular therapies that would not require patient-matched donors.
Several caveats apply. All data derive from preclinical mouse models and in vitro human cell experiments; clinical translation remains years away. The summary is based on the abstract only, so mechanistic depth and safety data cannot be fully assessed. Commercial conflicts of interest exist, as several authors co-founded Myelogene Inc. to develop this technology.
Key Findings
- Long-term GMP expansion achieved in vitro for both mouse and human cells while preserving myeloid differentiation potential.
- Myeloperoxidase identified as a novel regulator of GMP proliferation, a potential new engineering target.
- CAR-GMPs suppressed CD19-positive leukemia and HER2-positive solid tumors in preclinical models.
- New IgG Fc-domain CAR design recruits host immune cells and functions across MHC mismatches, enabling allogeneic use.
- Transferred GMPs engrafted hematopoietic niches and restored antibacterial immunity in chronic granulomatous disease mice.
Methodology
The study used mouse and human GMP cultures under defined conditions, with in vitro expansion and genetic engineering followed by adoptive transfer into disease mouse models. Cancer efficacy was tested against CD19-positive leukemia and HER2-positive solid tumor models, including immunocompetent allogeneic settings. Mechanistic studies identified myeloperoxidase as a proliferation regulator.
Study Limitations
All findings are preclinical, derived from mouse models and human cell cultures, with no clinical trial data yet available. The summary is based on the abstract only, so full methodology, safety profiles, and mechanistic details cannot be evaluated. Several lead authors have disclosed financial conflicts of interest as co-founders of Myelogene Inc., which has licensed the underlying patents.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: